← Back to Subjects ororo.world

Chapter 2: Scope and Importance of Biotechnology

In Indian villages, the neem tree has never been treated as anything unusual. Its twigs clean teeth, its leaves are stored with grain to keep insects away, and its oil has been rubbed on crops and skin for as long as anyone can remember. Nobody thought of this as a discovery. It was simply knowledge that had always been there, passed from one generation to the next without a single document to prove it.

Then, in the 1990s, something strange happened. A patent was granted in Europe on a method of controlling fungi on plants using oil obtained from neem seeds. The patent was held by an American company together with the United States Department of Agriculture. On paper, a use of neem that Indian farmers had practised for centuries now belonged, legally, to someone else.

The response was a legal battle that lasted years. A group of objectors, including the Indian environmental activist Vandana Shiva along with European organic farming organisations, challenged the patent before the European Patent Office, arguing that the fungicidal use of neem was not new at all. In 2000 the European Patent Office revoked the patent, and the revocation was upheld on appeal in 2005.

One tree, and a courtroom argument about who is allowed to own an idea. That is where biotechnology’s questions of law, ethics and public trust begin.

Diagram

Fig. 2.1 – A neem tree on one side and a stamped patent document on the other, joined by a balance scale; label the tree “traditional knowledge”, the document “patent claim”, and the scale “who owns an idea?”

NoteCuriosity Corner

Q1. Biology, chemistry, physics, mathematics, engineering and computer science — how can a single subject borrow from all of them at once? Q2. If a plant has been used in a country for hundreds of years, can a company somewhere else claim legal rights over that use? Q3. A patent, a trademark and a geographical indication all protect something. What exactly does each one protect? Q4. Who in India decides whether a genetically modified crop may be planted in an open field? Q5. Why do scientists working with helpful microbes and useful genes still have to argue about ethics and safety?

Every one of these questions is answered somewhere in this chapter. Read on, and check your answers as you go.

2.1 Biotechnology as an Interdisciplinary Field

Most school subjects have clear boundaries. Biology deals with living things, chemistry with substances and reactions, physics with matter and energy. Biotechnology sits deliberately across all of these boundaries, because the job it sets itself — using living systems to make useful products — cannot be done from inside any one of them.

Think about what is actually needed to make a medicine inside a bacterium. Someone must understand the organism, someone must understand the chemistry of the molecule being made, someone must build the vessel it grows in, and someone must make sense of the data at the end. No single discipline supplies all four.

NoteDefinition

Biotechnology is an interdisciplinary field, because it draws principles, knowledge and techniques from several sciences and from engineering, and combines them to use biological systems for practical purposes.

What Each Discipline Contributes

Biology is the core. Genetics, microbiology, molecular biology, cell biology and biochemistry together tell us what living organisms are made of, how they work, and which parts of them can be safely altered. Without this base, everything else would be blind tinkering.

Chemistry explains the structure and reactivity of biomolecules, enzymes and metabolic pathways. A protein is, after all, a chemical; knowing its bonds, charges and stability is what allows a biotechnologist to purify it without destroying it.

Physics supplies instrumentation and analysis. Spectrophotometry, centrifugation and electrophoresis are all physical techniques — they depend on the absorption of light, on centrifugal force, and on the movement of charged particles in an electric field. You will use this link directly in the ISC practical work, where a colorimeter or spectrophotometer is used to read the concentration of a coloured product.

Mathematics and statistics are needed for experimental design, data interpretation, growth modelling, bioprocess optimisation, probability and biostatistics. A result from three test tubes means nothing until you know whether the difference between them is real or accidental.

Engineering, particularly biochemical and process engineering, designs bioreactors, scales fermentation up from a flask to thousands of litres, and keeps production efficient. A microbe that grows beautifully on a laboratory bench will die in a large tank unless someone has worked out its oxygen supply, stirring and heat removal.

Computer science and bioinformatics have become indispensable in the era of genomics and proteomics. They analyse very large biological datasets, model molecular structures, and help design genetically modified organisms. A single genome sequence contains far more information than any person could read by eye.

Diagram

Fig. 2.2 – A central hexagon labelled “Biotechnology” with six arrows feeding into it from labelled boxes: Biology, Chemistry, Physics, Mathematics and Statistics, Engineering, Computer Science and Bioinformatics; three arrows leading out to Medicine, Agriculture, Environment

A Bridge, Not a Branch

Because biotechnology both draws from these disciplines and gives back to them, it does not belong to any single branch of science. It acts as a bridge connecting them, which is exactly what makes it a truly interdisciplinary domain. Its results then feed into medicine, agriculture and environmental science, as Fig. 2.2 shows.

The industrial production of citric acid using the fungus Aspergillus niger is a good illustration of the bridge at work. Biology chose the organism, chemistry defined the pathway and the product, engineering built the fermenter, and statistics decided which growth conditions gave the best yield. Remove any one contribution and the process stops.

NoteExam Corner

Q. If biology is the “core” of biotechnology, why can a biologist not run a biotechnology industry alone?

A. Because knowing how an organism behaves does not tell you how to build the vessel it must grow in, how to measure the product, or how to prove that your yield improvement is genuine rather than chance. Those answers come from engineering, physics and statistics.

NoteCuriosity Corner

Q1. Biology, chemistry, physics, mathematics, engineering and computer science — how can a single subject borrow from all of them at once?

A. Because biotechnology is defined by a goal rather than by a body of knowledge. Its goal — making useful products from living systems — needs an organism (biology), an understanding of the molecules involved (chemistry), instruments to measure them (physics), analysis of the readings (mathematics and statistics), equipment to scale the process up (engineering) and software to handle the data (computer science). Each discipline supplies one necessary piece, so biotechnology borrows from all of them and belongs exclusively to none.

2.2 Importance of Biotechnology

Biotechnology has become one of the most powerful scientific tools of the modern era for a simple reason: it takes biological knowledge and turns it into things people can actually use. By working with living organisms, cells, enzymes and biomolecules, it addresses problems that societies everywhere are struggling with — food security, healthcare, industrial sustainability, environmental protection and the advance of science itself.

It is worth noticing what these five areas have in common. In each case, the older solution was chemical, mechanical or simply slow, and the biological solution turns out to be more precise, less wasteful, or both.

In Agriculture

Biotechnology raises both the productivity and the quality of crops. Traditional breeding methods are time-consuming and are often blocked by species barriers — a useful character present in a wild relative may take many generations to move into a cultivated variety, and a character present in a bacterium cannot be bred into a plant at all.

Biotechnology overcomes these limits in two ways. It allows precise genetic modification, so that a single desired character can be transferred without dragging unwanted ones along with it, and it allows rapid multiplication of desirable plant varieties in culture. It also reduces dependence on chemical fertilisers and pesticides, which promotes sustainable agriculture and lowers the environmental damage that heavy chemical use causes.

NoteCompare Table

Traditional breeding vs biotechnological crop improvement | Feature | Traditional breeding | Biotechnological methods | |—|—|—| | Time required | Many generations, often years | Comparatively rapid | | Species barrier | Cannot cross unrelated species | Genes can be moved across species | | Precision | Whole sets of genes move together | A single chosen gene can be transferred | | Multiplication of a good variety | Limited by seed and season | Rapid multiplication in culture | | Dependence on chemicals | Usually unchanged | Often reduced |

In Healthcare

In healthcare, biotechnology has changed how diseases are diagnosed, prevented and treated. It allows medical products to be made using biological systems rather than extracted from scarce natural sources, which makes them safer, more effective and more affordable.

There is a second advantage that matters clinically. Biotechnological medicines are often more specific in their action than conventional drugs — they are designed to act on one target — and greater specificity generally means fewer side effects.

In Industry

Industrial biotechnology replaces harsh chemicals with biological catalysts, that is, enzymes. Because enzymes work at moderate temperatures and near-neutral pH, processes that once needed strong acids, high heat or high pressure can be run under gentler conditions. The result is industry that is both cleaner and more energy-efficient.

Food processing, textiles, detergents, pharmaceuticals and biofuel production all now depend heavily on biotechnological processes.

In Environmental Protection

Living organisms are used to degrade pollutants, treat wastes and recycle organic matter, which gives biotechnology a direct role in protecting and restoring the environment. Instead of merely moving a pollutant elsewhere, microbial action can break it down into harmless products. In this sense biotechnology helps maintain ecological balance rather than simply managing damage.

In Scientific Research

Finally, biotechnology has transformed biological research itself by making detailed study of genes, proteins and metabolic pathways possible. It supports advanced fields such as genomics and proteomics, personalised medicine and bioinformatics, and these in turn deepen our understanding of life processes and open fresh avenues for innovation.

Flowchart

FC 2.1 – From knowledge to public benefit: biological knowledge → laboratory research → identification of a useful organism, gene or enzyme → small-scale process development → scale-up and testing → regulatory approval → product reaching farms, hospitals, industry or the environment

NoteExam Corner

Q. Biotechnology is often called a “sustainable” technology. What exactly makes it sustainable?

A. Three things together — it uses renewable biological material rather than finite chemical feedstocks, it works under mild conditions and so consumes less energy, and its products and wastes are usually biodegradable. Sustainability here is not a slogan; it is a consequence of using living catalysts instead of harsh chemistry.

NoteTry Yourself

List the household products you used this morning. Mark the ones that involved an enzyme, a fermentation, or a cultured microorganism at some stage of their manufacture.

2.3 Branches of Biotechnology

Biotechnology is usually described in terms of branches — not because the science divides neatly, but because different branches answer different questions. Each branch is named after the area of life it serves, and the same core techniques often reappear in several of them.

A colour code is sometimes used informally for these branches (green for agriculture, red for medicine, white for industry, blue for marine work). The names below are the ones you should know for the examination; the colours are only a memory aid.

Diagram

Fig. 2.3 – A wheel with “Biotechnology” at the hub and eight labelled spokes: Agricultural, Animal, Medical, Industrial, Microbial, Immunology and Health Care, Nanobiotechnology, Energy and Environmental

2.3.1 Agricultural (Plant) Biotechnology

Agricultural biotechnology applies biotechnological techniques to improve crop plants and livestock. Its primary objective is to increase agricultural productivity while keeping the system environmentally sustainable.

NoteDefinition

Agricultural biotechnology is the branch of biotechnology that uses biological techniques to improve crop plants and farm animals, so as to raise productivity without harming the environment.

Its major applications are:

1. Development of genetically modified (GM) crops with improved traits.
2. Crop improvement through plant tissue culture; micropropagation allows rapid multiplication of disease-free plants.
3. Use of biofertilisers and biopesticides as eco-friendly alternatives to chemicals, which prevents chemical pollution.
4. Development of stress-tolerant crops resistant to drought, salinity and temperature extremes.

Bt cotton is the standard Indian example. It is a genetically modified crop carrying a gene from the bacterium Bacillus thuringiensis. The gene directs the plant to produce a protein that is toxic to certain insect pests but harmless to humans, so the plant defends itself instead of being sprayed. Cultivation of Bt cotton has significantly reduced pesticide usage and increased cotton yield.

NoteExam Corner

Q. If the Bt protein kills insects, why is it considered safe for people?

A. The protein needs the alkaline gut and specific receptors found in certain insect larvae to become active and bind. The human stomach is strongly acidic and lacks those receptors, so the protein is simply digested like any other dietary protein.

2.3.2 Animal Biotechnology

Animal biotechnology applies the same set of tools to farm animals and laboratory animals — improving breeds, protecting herds from disease, and using animals or animal cells to make useful products.

NoteDefinition

Animal biotechnology is the branch of biotechnology that uses modern biological techniques to improve animal breeding, health and productivity, and to obtain useful products from animals or animal cells.

Its major applications are:

1. Improvement of livestock breeds through artificial insemination and embryo transfer technology.
2. Production of veterinary vaccines and diagnostic kits for animal diseases.
3. Use of animal cell culture to produce vaccines and therapeutic proteins.
4. Conservation of endangered animal species through preserved germplasm.

Embryo transfer technology is a good working example. Embryos from a genetically superior cow are collected and transferred into ordinary recipient cows, which carry the pregnancies. One superior animal can therefore contribute far more offspring in a lifetime than normal reproduction would allow.

2.3.3 Medical Biotechnology

Medical biotechnology focuses on improving human health by developing therapeutic agents, diagnostic tools and advanced treatment methods.

NoteDefinition

Medical biotechnology is the branch of biotechnology concerned with the development of medicines, diagnostic techniques and treatment methods for human disease using biological systems.

Its applications are:

1. Production of recombinant proteins such as insulin, growth hormone and interferons.
2. Development of vaccines and antibiotics for infectious diseases.
3. Use of molecular diagnostic techniques such as ELISA and PCR for early detection of disease.
4. Advancement of gene therapy and stem cell therapy for inherited and degenerative disorders.

Human insulin made by recombinant DNA technology has replaced the animal-derived insulin that diabetic patients once depended on. Because it is structurally identical to natural human insulin, it is safer and more effective than insulin purified from cattle or pig pancreas, which differed slightly in structure and could provoke immune reactions in some patients.

2.3.4 Industrial Biotechnology

Industrial biotechnology uses microorganisms and enzymes to manufacture products on a commercial scale by environmentally friendly processes.

NoteDefinition

Industrial biotechnology is the branch of biotechnology that uses microorganisms and their enzymes for large-scale manufacture of useful products through environmentally friendly processes.

Its applications are:

1. Production of enzymes for detergents, food processing and textiles.
2. Fermentation-based production of alcohol, organic acids and vitamins.
3. Development of biofuels such as bioethanol and biodiesel.
4. Manufacture of biodegradable plastics.

Protease enzymes added to detergents break down protein-based stains such as blood, egg and milk at lower washing temperatures. Less heating is needed, so energy consumption falls while washing efficiency improves — an ordinary example of a biological catalyst quietly replacing a harsh chemical one.

2.3.5 Microbial Biotechnology

Microbial biotechnology exploits bacteria, fungi, algae and viruses for beneficial applications across many sectors. It overlaps heavily with industrial biotechnology, the difference being one of emphasis: here the organism itself is the centre of attention.

NoteDefinition

Microbial biotechnology is the branch of biotechnology that uses microorganisms — bacteria, fungi, algae and viruses — to obtain useful products and services.

Its applications are:

1. Large-scale production of antibiotics by culturing microbes in bioreactors.
2. Production of Single Cell Protein (SCP) as an alternative protein source.
3. Treatment of industrial and domestic waste through bioremediation.
4. Synthesis of enzymes, organic acids and vitamins.

Penicillin, one of the earliest and most widely used antibiotics, came from the mould Penicillium notatum; commercial manufacture today uses the higher-yielding species Penicillium chrysogenum grown in large fermenters. The shift from the original discovery strain to a production strain is typical of industrial microbiology — what works in a laboratory dish is rarely what works in a factory.

2.3.6 Immunology and Health Care

This branch applies biotechnological tools to understand, manipulate and use the immune system for the diagnosis, prevention and treatment of disease. It has made immunology more precise, more scalable and safer, and it now underpins much of modern medicine and public health.

NoteDefinition

Biotechnology in immunology is the application of biotechnological tools and techniques to study and use the immune system for diagnosis, prevention and treatment of diseases.

Its applications are:

1. Development of recombinant vaccines, DNA vaccines, mRNA vaccines and edible vaccines.
2. Production of monoclonal antibodies using hybridoma technology.
3. Immunodiagnostic tests such as ELISA.
4. Immunotherapy for cancer and autoimmune diseases.

Monoclonal antibodies are widely used in cancer treatment and in managing autoimmune disorders, precisely because every antibody in the preparation is identical and recognises a single target. That high specificity is what allows a drug to act on diseased cells while largely leaving healthy ones alone.

2.3.7 Nanobiotechnology

Nanobiotechnology combines biotechnology with nanotechnology to develop nanoscale tools and materials for biological use. It involves manipulating, characterising and using materials and devices at the nanometre scale in order to study and interact with biological systems.

NoteDefinition

Nanobiotechnology is the branch of biotechnology that designs and uses materials and devices at the nanometre scale for biological and medical applications.

The scale is the whole point. At a few nanometres, a particle is comparable in size to the biological molecules and structures it must work with, so it can travel where a conventional drug particle cannot.

Its applications are:

1. Targeted drug delivery systems.
2. Development of biosensors for disease detection.
3. Cancer diagnosis and therapy.
4. Tissue engineering and regenerative medicine.

Nanoparticles are used to carry anti-cancer drugs directly to tumour cells. Because the drug travels packaged rather than free in the bloodstream, damage to healthy tissue and the severity of side effects are both reduced. Nanobiotechnology also holds promise for DNA chips and for understanding fundamental biological processes.

2.3.8 Energy and Environmental Biotechnology

Environmental biotechnology applies biological systems to protect, restore and sustain the environment, while the energy side of the same branch uses living systems to produce renewable fuels. The two belong together because both replace a fossil-based or chemical route with a biological one.

NoteDefinition

Environmental biotechnology is the branch of biotechnology that uses biological processes and organisms to prevent, control and reverse environmental pollution, and to produce renewable sources of energy.

Its applications are:

1. Biological treatment of sewage.
2. Bioremediation of oil spills, heavy metals and toxic wastes.
3. Composting and recycling of organic waste.
4. Control of air and water pollution.
5. Production of renewable energy — biogas from organic waste, and bioethanol and biodiesel as fuels.

Certain bacteria, such as Pseudomonas putida, can degrade hydrocarbons present in oil spills. Instead of being skimmed off and dumped elsewhere, the oil is broken down into simpler, less harmful compounds, which reduces long-term environmental damage. On the energy side, biogas plants use anaerobic microorganisms to convert cattle dung and crop residues into methane-rich fuel gas, turning a disposal problem into a village energy supply.

NoteBioethics

Do the benefits of a new branch justify its risks before those risks are fully known? Nanobiotechnology illustrates a difficulty that runs through every branch on this list. Nanoparticles small enough to enter cells and cross biological barriers are useful for exactly that reason — but the same property makes their long-term behaviour in the body and in the environment hard to predict. Supporters argue that the medical gains, particularly in cancer therapy, are real and immediate, and that withholding a working treatment has its own cost. Critics argue that a material should be shown to be safe before it is widely released, not after. The usual safeguard is staged approval: laboratory testing, then limited clinical or field trials, then regulated release with continued monitoring — the same principle you will meet in Section 2.7 for genetically modified organisms.

2.4 Intellectual Property and the Need for IPRs

Scientific research and technological innovation are the outcome of sustained intellectual effort, creativity and financial investment. In biotechnology this is unusually true. Developing a genetically modified organism, a vaccine, a diagnostic kit, a recombinant protein or an industrial enzyme takes years of experimentation, expensive infrastructure and skilled people.

Now consider what happens without legal protection. The moment such an innovation is published or marketed, anyone can copy it — and the copier has none of the development costs to recover. Researchers and industries would soon stop investing, not because they had lost interest, but because there would be no way to recover what they had spent.

To safeguard these intellectual creations and to encourage further innovation, Intellectual Property Rights have been established.

NoteDefinition

Intellectual Property Rights (IPRs) are legally enforceable rights granted to individuals or organisations over their intellectual creations, giving the creator exclusive control over the use, manufacture, sale and commercial exploitation of the invention or creation for a specified period.

Notice the two limits built into that definition. The right is exclusive, but it is granted only for a specified period, after which the knowledge passes into public use. Intellectual property law is therefore a bargain, not a gift: society grants a temporary monopoly, and in exchange the inventor discloses the invention instead of hiding it.

Discovery and Invention

Not everything that comes out of a laboratory can be owned. The law draws a sharp line between a discovery and an invention, and only the second is patentable.

A discovery is the finding of something that already existed in nature, whether or not anyone knew about it. An invention is something new made by human intervention — a device, a process, a composition that did not exist until someone created it.

NoteDefinition

A discovery is the recognition of a substance, organism or natural law that already exists in nature. An invention is a new and non-obvious product or process created by human effort.

NoteCompare Table

Discovery vs Invention | Feature | Discovery | Invention | |—|—|—| | What it is | Finding what already exists in nature | Creating something that did not exist before | | Human role | Observation and identification | Design and technical intervention | | Examples | A new bacterial species in a hot spring; the law of gravitation; the process of photosynthesis | A method of producing a protein in a bacterium; a diagnostic kit; a new fermentation process | | Patentable? | No | Yes, if it also meets the legal criteria |

This distinction explains many decisions that otherwise look arbitrary. Isolating a wild microorganism from soil is a discovery. Working out an industrial process that uses that microorganism to make a useful acid, at a yield nobody had achieved before, is an invention.

NoteExam Corner

Q. A scientist identifies a gene in a plant that makes it drought-tolerant. Is that patentable?

A. Merely finding the gene in the plant is a discovery — the gene was already there. What may be patentable is what the scientist then builds with it: a specific construct, a process for transferring it, or a modified organism expressing it. The dividing line is human technical intervention, not effort or expense.

Role of IPRs in Biotechnology

IPRs play a crucial part in the growth of biotechnology by:

1. Encouraging innovation and original research.
2. Protecting scientific discoveries and inventions from unauthorised use.
3. Facilitating technology transfer from laboratories to industries.
4. Supporting economic growth and global competitiveness.
5. Ensuring recognition and financial reward for inventors.

The third point deserves attention, because it is easy to miss. A university laboratory rarely manufactures anything itself; it licenses its protected invention to a company that can. Without a right to license, there is nothing to hand over, and good laboratory work simply stops at the laboratory door.

NoteSide Note

A useful memory hook for why IPRs matter is I-PROTECT — Innovation encouragement, Protection of inventions, Recognition to inventors, Organised commercialisation, Technology transfer, Economic growth, Collaboration between industry and research, and Trust in research systems.

Two Broad Areas of Intellectual Property

Intellectual property can usefully be divided into two main areas:

1. Artistic intellectual property: protection of distinctive signs, in particular trademarks and geographical indications.
2. Commercial or industrial intellectual property: protection given primarily to stimulate innovation, design and the creation of technology.

The first protects identity — who a product belongs to and where it comes from. The second protects the technology itself. A single biotechnology product often needs both: the process by which a vaccine is made falls in the second category, while the brand name it is sold under falls in the first.

Diagram

Fig. 2.4 – A two-column chart headed “Intellectual Property”; left column “Artistic (distinctive signs)” listing trademark and geographical indication; right column “Commercial/Industrial (technology)” listing patent, trade secret and plant breeders’ rights; copyright shown bridging the two

Why Biotechnology Needs IPRs Particularly

IPRs are especially significant in biotechnology for reasons that follow directly from how the field works:

1. Biotechnological research is expensive and time-consuming.
2. Legal protection ensures a return on that investment.
3. Ethical commercialisation is promoted, because ownership is declared openly rather than concealed.
4. Collaboration between research institutions and industries is made possible.
5. Innovation is encouraged at both national and global levels.

NoteBioethics

Should living material be owned at all? The idea of holding legal rights over genes, cells and organisms troubles many people. Those in favour argue that the right is granted over a human technical achievement — a process, a construct, a modified strain — and not over life itself, and that without such rights costly medical research would not be funded. Those against argue that living material is a shared inheritance, that ownership claims can restrict access to essential medicines and seeds, and that communities whose traditional knowledge made the innovation possible are rarely compensated. The safeguards that have emerged include the exclusion of naturally occurring material from patentability, compulsory licensing during public health emergencies, and separate legislation recognising farmers’ and breeders’ rights, which you will meet in the next section.

2.5 Types of Intellectual Property Rights

Intellectual property is not a single right. It is a set of six different rights, each designed to protect a different kind of creation, and each with its own conditions and duration. Choosing the wrong one is as damaging as choosing none, so it is worth understanding what each actually covers.

2.5.1 Patent

A patent is an exclusive legal right granted by the government to an inventor for a new, useful and non-obvious invention. It prevents others from making, using, selling or importing the patented invention without permission. In biotechnology, patents may be granted for products, processes or technologies that show novelty and industrial applicability.

NoteDefinition

A patent is an exclusive right granted by the government to an inventor over a new, useful and non-obvious invention, preventing others from making, using, selling or importing it without permission for a fixed period.

Patentable Inventions in Biotechnology

1. Methods or processes: a new and non-obvious method of using a known compound — for instance biotechnological processes that yield useful proteins, enzymes, vaccines, biochemicals or secondary metabolites.
2. Composition: the compositional formula of beneficial products such as pharmaceuticals and reagents.
3. Products: new chemicals such as pesticides, additives, herbicides, insecticides and fungicides; genes including modified genes; expression vectors and probes; modified proteins; vaccines and therapeutic drugs.
4. New uses: a completely new use for a previously known compound or organism — such as exploiting a known microbe for the production of a drug it was not previously used for.
5. New methods of treatment or diagnosis: new treatment or diagnostic methods applicable to instruments and to industrial products such as dyes and flavour chemicals.

Criteria for Patentability

For an invention to qualify for a patent, it must satisfy three essential conditions together. Failing any one is enough for refusal.

1. Novelty: the invention must be new and not previously disclosed anywhere in the world.
2. Inventive step: it must not be obvious to a person skilled in the relevant scientific field.
3. Industrial applicability: it must have a practical and useful application.

The first criterion is stricter than students usually expect. “Not previously disclosed anywhere in the world” includes disclosure by the inventor — a scientist who publishes a paper before filing may have destroyed the novelty of their own invention.

NoteExam Corner

Q. Why does an invention have to be non-obvious as well as new? Isn’t being new enough?

A. Because a trivial change is technically new. If simply raising a reaction temperature by two degrees earned a twenty-year monopoly, patents would block ordinary practice rather than reward real innovation. The inventive-step test asks whether a competent scientist in that field would have arrived at it anyway.

Components of a Patent Document

A patent document is a structured legal and scientific record consisting of:

1. Title: indicates the nature of the invention.
2. Abstract: summarises the invention briefly.
3. Background of the invention: explains existing knowledge and its limitations.
4. Detailed description: provides complete technical details of the invention.
5. Claims: define the legal scope and extent of protection.
6. Drawings or diagrams: illustrate the invention, where required.

Of these, the claims matter most in a dispute. The description explains the invention; the claims decide exactly how much of it is fenced off.

Duration of patent protection: patents are generally valid for 20 years from the date of filing.

NoteReal Incident / Discovery

In the early 1970s, Stanley Cohen of Stanford University and Herbert Boyer of the University of California, San Francisco, worked out how to cut DNA from one organism and join it into a plasmid that could replicate inside a bacterium. It was the foundational technique of genetic engineering. Their universities filed for a patent on the process, and it was granted at the start of the 1980s. What is notable is how the patent was then used: rather than reserving the technique for one company, the universities licensed it widely and cheaply to anyone who wanted it. The result was an entire industry built on a shared method, and a demonstration that a patent can be used to spread a technology rather than lock it away.

Advantages of the Patent System

1. The patent is limited to a fixed period, during which the holder retains an exclusive right over the product or process.
2. Once granted, the patent is comparatively easy to maintain and enforce.
3. Misuse of what is covered by the patent can be prevented.

Disadvantages of the Patent System

1. Because a patent requires public disclosure, competitors learn how the product is made and can use that knowledge freely once protection expires.
2. Litigation over a patented product or process is highly expensive.
3. Information related to the invention but not actually covered by the claims can be used by others.

In India, genetically modified plants and animals are not patentable. Plant varieties produced by traditional cross-breeding may instead be protected under Plant Breeders’ Rights, which are dealt with in Section 2.5.6.

2.5.2 Trademark

A trademark is a distinctive word, name, symbol, logo or design that identifies the goods or services of one organisation and distinguishes them from those of others. Trademarks protect commercial identity and reputation rather than technology.

NoteDefinition

A trademark is a distinctive sign — a word, name, symbol, logo or design — used to identify the goods or services of one organisation and distinguish them from those of others.

Trademarks are important because they:

1. Prevent imitation and counterfeiting.
2. Help consumers identify genuine products.
3. Build brand loyalty and trust.
4. Enhance market value.

The brand name and logo under which a vaccine or a pharmaceutical drug is sold are protected as trademarks, so that only authorised manufacturers may use them. In medicine this is a safety matter as much as a commercial one: a counterfeit product carrying a trusted name can reach a patient who has no way of telling the difference.

2.5.3 Trade Secrets

Trade secrets are confidential business information that gives a competitive advantage. Unlike patents, they are neither disclosed nor registered, and they remain protected for as long as secrecy is maintained. Manufacturing processes, product formulations, industrial techniques and proprietary protocols are typical examples.

NoteDefinition

A trade secret is confidential business information that gives its holder a competitive advantage and is protected only for as long as it is kept secret.

Advantage: protection has unlimited duration, and no registration or disclosure is required.

Limitation: once the information is disclosed, or independently discovered by someone else, the protection is permanently lost.

NoteCompare Table

Patent vs Trade secret | Feature | Patent | Trade secret | |—|—|—| | Disclosure | Invention must be published in full | Kept confidential | | Registration | Required, with examination | None | | Duration | 20 years from filing | Unlimited, while secrecy lasts | | Protection against independent discovery | Yes | No | | Cost | High filing and litigation costs | Low, but needs constant internal security | | Best suited to | Inventions that can be reverse-engineered from the product | Processes that cannot be worked out from the product |

2.5.4 Copyright

Copyright protects original literary, artistic, scientific and educational works. In biotechnology it applies to the expression of ideas, not to the scientific discoveries themselves — the way a finding is written up is protected, while the finding is not.

NoteDefinition

Copyright is the right granted over original literary, artistic, scientific and educational works, protecting the particular expression of an idea rather than the idea itself.

Works protected by copyright include:

1. Textbooks and reference books.
2. Research papers and review articles.
3. Scientific diagrams and illustrations.
4. Computer software and databases.

Duration of copyright: in India, copyright in a literary, scientific or artistic work generally lasts for the author’s lifetime and for a further 60 years counted from the year following the author’s death; the period is calculated differently for films and sound recordings.

A biotechnology textbook, a piece of bioinformatics software or a digital genomic database is protected under copyright law, which prevents unauthorised reproduction.

2.5.5 Geographical Indications (GI)

A Geographical Indication is a sign used on products that originate from a specific geographical region and possess qualities or a reputation arising from that origin.

NoteDefinition

A Geographical Indication (GI) is a sign used on a product that comes from a particular geographical region and owes its distinctive qualities or reputation to that origin.

Its significance is that it:

1. Protects traditional and indigenous knowledge.
2. Prevents misuse of regional product names.
3. Promotes rural development and exports.

Basmati rice, known for its aroma and long grains, and Darjeeling tea, valued for its distinctive flavour and quality, are the standard Indian examples. A GI belongs to a whole community of producers in a region rather than to a single firm — which is what makes it the natural instrument for protecting knowledge that no one person invented.

NoteCuriosity Corner

Q2. If a plant has been used in a country for hundreds of years, can a company somewhere else claim legal rights over that use?

A. It can attempt to, and such claims have been made and later overturned. The claim fails on the criterion of novelty: an invention must not have been previously disclosed anywhere in the world, and a use practised openly for generations is prior knowledge, even where it was never written down. The difficulty is one of evidence — undocumented traditional knowledge is hard to prove in a patent office. This is why India has built digital libraries of traditional knowledge and why Geographical Indications and the PPV and FR Act exist: they give community knowledge a documented, legally recognised form.

2.5.6 Plant Breeders’ Rights and the PPV and FR Act, 2001

The Protection of Plant Varieties and Farmers’ Rights (PPV and FR) Act, 2001 is Indian legislation that balances the rights of plant breeders, farmers and researchers. It promotes innovation in plant breeding while protecting farmers’ interests, ensuring ethical use of plant genetic resources and supporting sustainable agricultural development.

Plant Breeders’ Rights protect a new variety created through breeding procedures and selection. Farmers’ Rights mean that farmers keep the right to produce seed from the crops they grow and to raise the next season’s sowing from their own harvest.

NoteDefinition

Plant Breeders’ Right (PBR) is the protection given to a new plant variety developed through breeding and selection. Farmers’ Right is the corresponding right of a farmer to save, use, sow, exchange and sell seed from their own harvest.

Objectives of the PPV and FR Act:

1. Encourage the development of new plant varieties.
2. Recognise farmers as cultivators and conservers of biodiversity.
3. Protect traditional plant genetic resources.
4. Ensure equitable benefit sharing.

Rights of plant breeders: to produce, sell, market and distribute the registered plant variety.

Rights of farmers:

1. The right to save, use, exchange and sell farm produce.
2. Recognition and reward for traditional knowledge.
3. Compensation if a crop fails because of defective seed.

A newly developed high-yielding rice variety can be registered under the PPV and FR Act by its breeder, while the farmers who grow it retain the right to save and reuse seed from their own harvest. Note what the Act does not permit: the farmer may sell saved seed as grain, but not under the breeder’s registered brand name.

2.5.7 Choosing the Right Form of Protection

Since the six rights protect different things, the practical question for a biotechnologist is which one fits the creation in hand. The choice follows from the nature of what is being protected and from how easily a competitor could work it out independently.

An invention that can be reverse-engineered from the product itself is best patented, because secrecy would fail anyway. A manufacturing process that leaves no trace in the finished product may be better kept as a trade secret, since protection then lasts indefinitely. A product’s name and packaging need a trademark; the manual and software that go with it are covered by copyright; a regional agricultural product needs a GI; and a new plant variety needs registration under the PPV and FR Act.

NoteSide Note

A one-line memory hook for the six: patent protects the invention, trademark protects the name, copyright protects the expression, trade secret protects secrecy, GI protects the place, and PPV and FR protects plants and farmers.

Diagram

Fig. 2.5 – A decision tree headed “What are you protecting?” branching to: a new process or product → patent; a process that cannot be reverse-engineered → trade secret; a name or logo → trademark; a written or software work → copyright; a region-linked product → geographical indication; a new plant variety → PPV and FR registration

NoteCuriosity Corner

Q3. A patent, a trademark and a geographical indication all protect something. What exactly does each one protect?

A. A patent protects a new, non-obvious and industrially useful invention — the technology itself — for 20 years from filing, and requires full public disclosure in exchange. A trademark protects a distinctive name, logo or symbol that identifies whose product it is, guarding commercial identity rather than technology. A geographical indication protects the link between a product and the place it comes from, and belongs to all the producers of that region rather than to one owner. In short: the patent protects what was invented, the trademark protects who made it, and the GI protects where it comes from.

2.6 Ethical, Legal and Social Issues (ELSI)

Every technology raises the question of whether something ought to be done, and not merely whether it can be done. In biotechnology that question arrives early and often, because the subject deals directly with living organisms and with life processes themselves.

ELSI stands for Ethical, Legal and Social Issues. The term refers to the moral, legal and societal concerns that arise from the rapid advancement and application of biotechnology — questions about human dignity, safety, justice, responsibility and social impact.

NoteDefinition

Ethical, Legal and Social Issues (ELSI) are the moral, legal and societal concerns raised by the development and application of biotechnology, particularly those affecting human dignity, safety, justice, responsibility and social impact.

Modern technologies such as genetic engineering, stem cell research, reproductive technologies and nanotechnology have significantly influenced individuals and society. Understanding ELSI is therefore essential if biotechnological progress is to occur in a responsible, safe and socially acceptable manner.

Why ELSI Must Be Studied

The impact of biotechnology is examined not only by scientists but also by philosophers, sociologists, ethicists, psychologists and policymakers. ELSI studies help in:

1. Assessing the ethical acceptability of new technologies.
2. Framing laws and regulations.
3. Evaluating social consequences.
4. Protecting vulnerable groups.
5. Ensuring responsible use of public resources.

That last point explains why these debates belong to everyone. Biotechnology research is often funded by the public, so stakeholders naturally disagree about how the money should be used. Some hold that biotechnology will bring long-term benefits to society; others fear it may create ethical risks, social inequality and environmental harm. Neither position can simply be declared correct, which is precisely why a structured discussion is needed.

The Common Example: In Vitro Fertilisation (IVF)

In vitro fertilisation is the standard example used to introduce ELSI, because a single well-established medical procedure raises ethical, legal and social questions all at once.

NoteDefinition

In vitro fertilisation (IVF) is a technique in which fertilisation of an egg by sperm takes place outside the human body in the laboratory, followed by implantation of the resulting embryo into the uterus.

Diagram

Fig. 2.6 – Outline of IVF: egg retrieval and sperm collection → fertilisation in a culture dish → early embryo development in the incubator → transfer of the embryo to the uterus; label the point at which surplus embryos are frozen

Ethical Concerns Related to IVF

1. Individual autonomy: decisions about selecting embryos may interfere with natural processes.
2. Equality: the high cost of IVF limits access to wealthier individuals, creating social inequality.
3. Protection of vulnerable groups: women may be exploited for egg donation or surrogacy.
4. Respect for human life and dignity: ethical questions arise about unused or discarded embryos.
5. Commercialisation of reproduction: treating human reproduction as a commercial service raises moral objections.
6. Use of public resources: the allocation of funds to IVF as against basic healthcare is debated.

Notice how these six concerns sort themselves into the three ELSI headings. Autonomy and respect for human life are ethical; exploitation and commercialisation call for legal regulation; and unequal access and the use of public funds are social questions.

NoteBioethics

Should parents be allowed to choose an embryo’s characteristics? When embryos can be screened before implantation, selection becomes possible — and this raises the concern about “designer babies”, where non-medical traits might be chosen. Those in favour of screening point out that it can prevent a child being born with a severe inherited disease, and argue that parents already make many decisions on a child’s behalf. Those against argue that selecting for non-medical characteristics treats a child as a product to specification, that it could deepen social inequality if only the wealthy have access, and that it implies certain kinds of people are less worth being born. Most regulatory systems respond by drawing a line rather than banning the technique: screening is permitted for serious medical conditions and prohibited for traits such as appearance, and in India sex selection is a criminal offence.

NoteSide Note

Similar arguments surround stem cell research. Obtaining embryonic stem cells involves the destruction of an embryo, which some regard as equivalent to ending potential human life, and this concern has led several countries to restrict such work. Adult stem cells raise no comparable objection, since no embryo is destroyed. You will study the biology of stem cells in Class XII.

Legal Issues in Biotechnology

Legal issues arise from:

1. Regulation of genetically modified organisms (GMOs).
2. Patenting of genes and living organisms.
3. Protection of patient rights and genetic privacy.
4. Biosafety and environmental laws.

Governments frame laws and regulatory frameworks so that biotechnology is used lawfully and ethically. Ethics identifies what ought to happen; law is how a society makes it happen in practice, with consequences attached.

Social Issues Related to Biotechnology

Biotechnology can affect society in several ways:

1. Genetic discrimination based on a person’s DNA information — for instance in employment or insurance.
2. Unequal access to advanced therapies.
3. Fear of misuse of genetic data.
4. Public mistrust arising from lack of awareness.

The last of these is often underestimated. A technology that the public does not understand tends to be resisted regardless of its merits, so public education and transparent policies are not optional extras — they are part of making the technology work.

NoteExam Corner

Q. If a technique is scientifically sound and medically useful, why should ethics be allowed to restrict it?

A. Because “it works” answers a different question from “it should be done”. A technique can be effective and still cause harm through unequal access, loss of privacy or exploitation of vulnerable people. Ethics does not usually block a technology outright; it sets the conditions — consent, regulation, equitable access — under which it may be used.

NoteCuriosity Corner

Q5. Why do scientists working with helpful microbes and useful genes still have to argue about ethics and safety?

A. Because the usefulness of a technique does not settle the questions that surround it. Biotechnology acts directly on living organisms and life processes, so its applications carry consequences beyond the laboratory — who gets access and who is excluded, whose personal genetic information is exposed, what happens to an organism once it leaves a controlled setting, and who bears the risk if something goes wrong. These are ethical, legal and social questions rather than scientific ones, and they cannot be answered by better experiments alone. Debating them openly is what keeps the technology publicly trusted and, in the long run, allows it to be used at all.

2.7 Biosafety and the Release of GMOs

A genetically modified organism is alive. That single fact separates biosafety from ordinary industrial safety. A spilled chemical stays where it falls and eventually breaks down; a released organism can grow, reproduce, spread and pass its altered genes to the next generation. Safety measures must therefore be designed for something that does not stay put.

Biosafety refers to the measures, practices and regulations designed to ensure the safe handling, containment and use of biological agents and genetically modified organisms. While biotechnology provides many benefits, it also poses potential risks to human health, the environment and biodiversity. Biosafety aims to minimise those risks while allowing scientific progress to continue.

NoteDefinition

Biosafety is the set of measures, practices and regulations that ensure the safe handling, containment and use of biological agents and genetically modified organisms, so as to protect human health, the environment and biodiversity.

Biosafety is essential because:

1. GMOs may spread unintentionally into the environment.
2. Laboratory work involves hazardous biological agents.
3. New biotechnological products may have unknown long-term effects.
4. Ethical and environmental concerns must be addressed.

Biosafety regulations vary from country to country, but governments, international organisations and scientific communities work together to develop shared guidelines and best practices. This cooperation is necessary for an obvious reason: pollen, seeds, insects and traded goods do not stop at national borders.

Release of Genetically Modified Organisms

Genetically modified crops, microorganisms and animals carry altered genetic traits. If they are released without proper control, they may cross-breed with natural species, disrupt ecosystems and reduce biodiversity.

The concern is not that the introduced trait is harmful in itself, but that it may prove advantageous in the wild. A gene that helps a crop survive drought or resist insects would help a related weed just as effectively, and a weed with that advantage can displace other species.

Strict containment, staged field trials and formal approval procedures are therefore required before any environmental release. GM crops are tested extensively to confirm that they do not harm beneficial insects such as pollinators, or the microorganisms that keep soil fertile.

Flowchart

FC 2.2 – Staged testing before release: laboratory work under containment → greenhouse or glasshouse trial → confined field trial in an isolated plot → multi-location open field trial with monitoring → biosafety and risk assessment review → approval or rejection → post-release monitoring

NoteExam Corner

Q. If a GM plant has been safe in the greenhouse for two years, why must it still go through confined field trials?

A. A greenhouse tests the plant; a field tests the ecosystem around it. Only in the field can you find out whether pollen reaches related wild species, whether soil organisms are affected, and how the plant behaves under real weather, pests and competition. Containment answers questions about the organism, not about its neighbours.

Genetic Contamination

Genetic contamination occurs when genetic material from GM organisms unintentionally mixes with non-GM crops, usually through cross-pollination or through mixing of seed and produce after harvest.

The consequences are economic as well as biological. Organic farmers can lose their certification and therefore their market; exports may face trade restrictions in countries with stricter rules; and public health concerns arise where a modified product enters the food chain without assessment.

Preventive measures include physical isolation of GM and non-GM fields, buffer zones of unmodified plants around a GM plot, and proper labelling and segregation of seed and produce at every stage of handling.

Laboratory Biosafety

Biotechnology laboratories often work with pathogenic microorganisms, recombinant DNA and genetically modified organisms. To prevent accidents and accidental release, laboratories must follow strict biosafety protocols:

1. Use of personal protective equipment (PPE).
2. Proper waste disposal, including sterilisation of all biological waste before it leaves the laboratory.
3. Secure containment facilities.
4. Training of personnel.

Handling pathogenic bacteria requires biosafety cabinets and sterilisation procedures to prevent exposure. You already meet the working end of this rule in the ISC practical course: autoclaving media and glassware, and disinfecting the work surface with alcohol before and after inoculation, are laboratory biosafety measures, not merely tidiness.

NoteSide Note

Laboratories are graded into biosafety levels according to the risk of the organisms handled, from BSL-1 for harmless organisms used in school and college teaching, up to BSL-4 for dangerous pathogens with no reliable treatment. A school laboratory working with Lactobacillus from curd sits at the lowest level.

Human Health Risk Assessment

Before a new biotechnological product is released into the market, it must be evaluated for allergenicity, toxicity and effects on human physiology. Rigorous testing followed by regulatory approval is what ensures consumer safety.

Allergenicity deserves particular attention with GM food. Since the modification usually means a new protein is present in the plant, the question asked is whether that protein resembles any known allergen, and whether it survives digestion long enough to provoke a reaction. GM food products accordingly undergo safety testing before approval for human consumption.

Ethical Aspects of Biosafety

Biosafety also carries an ethical responsibility in three areas:

1. The use and manipulation of living organisms.
2. The fair distribution of risks and benefits.
3. The protection of future generations.

The second of these is the one most often raised in public debate. If a GM crop increases a company’s profits and a consumer’s convenience, while the ecological risk is borne by farmers and communities near the fields, then benefit and risk have been distributed to different people. Ethical frameworks exist to guide scientists and policymakers so that biotechnology benefits society as a whole rather than a section of it.

NoteTry Yourself

Suppose a GM variety of a crop grown in your region were approved tomorrow. List three questions you would want answered before it was planted next to non-GM fields, and identify which of them is ethical, which is ecological and which is economic.

2.8 Genetic Engineering Approval Committee (GEAC)

Genetic engineering makes it possible to develop genetically modified organisms that benefit agriculture, medicine and industry. Their use and release, however, may pose risks to human health, biodiversity and the environment. Somebody, therefore, has to decide — case by case, before anything is planted or sold — whether a particular GMO is safe enough to be allowed out. In India that responsibility belongs to the Genetic Engineering Approval Committee.

The GEAC is the apex regulatory authority in India for evaluating and regulating activities that involve genetically engineered organisms and products. It functions under the Ministry of Environment, Forest and Climate Change (MoEF and CC), Government of India, and it ensures that genetic engineering activities are conducted in a safe, ethical and environmentally responsible manner.

NoteDefinition

The Genetic Engineering Approval Committee (GEAC) is the apex regulatory body in India, functioning under the Ministry of Environment, Forest and Climate Change, that evaluates and approves activities involving genetically engineered organisms and products, including their large-scale use and environmental release.

NoteSide Note

The committee was originally constituted as the Genetic Engineering Approval Committee, and this is the name used in the ISC syllabus. It was later renamed the Genetic Engineering Appraisal Committee, the change of word reflecting that its task is to appraise proposals rather than simply to clear them. The abbreviation GEAC is unchanged, and both expansions refer to the same body.

Why a Regulator Is Needed

GEAC is required because:

1. Genetic engineering causes permanent genetic changes, which are inherited and cannot simply be recalled.
2. GMOs may spread uncontrollably if left unregulated.
3. Long-term health and environmental effects may not be immediately evident.
4. Independent scientific assessment is necessary to maintain public trust.

The fourth reason is easy to overlook but is arguably the most practical. A company’s own safety data, however honest, will not convince a sceptical public. An independent authority whose approval is required makes the assessment credible to people who have no way of checking the science themselves.

Objectives of GEAC

1. To protect human health and the environment.
2. To regulate the use and release of GMOs.
3. To ensure compliance with biosafety standards.
4. To promote the responsible application of biotechnology.

Roles and Functions of GEAC

1. Approval of GMOs. GEAC approves the large-scale use of GM organisms, their environmental release and the commercial cultivation of GM crops. Approval is granted only after detailed biosafety and risk assessment.

2. Regulation of field trials. It authorises and monitors both confined and open field trials, which is how GMO safety is assessed under natural conditions rather than laboratory conditions.

3. Environmental risk assessment. It evaluates the impact of GMOs on biodiversity, on non-target organisms, and the possibility of gene flow to wild species.

4. Human health safety evaluation. It examines the toxicity, allergenicity and nutritional safety of GM products.

5. Post-approval monitoring. Even after approval, GEAC ensures continuous monitoring and compliance with biosafety guidelines. Approval is a stage in supervision, not the end of it.

6. Framing biosafety guidelines. It formulates rules for the safe handling, transport, storage and disposal of GM materials.

7. Advisory role. It advises the government on GMO-related policy and on India’s international biosafety obligations.

Flowchart

FC 2.3 – GEAC approval process: development of GMO → laboratory testing → field trials → biosafety assessment → GEAC evaluation → approval or rejection → post-release monitoring

As FC 2.3 shows, the sequence moves steadily from the most controlled setting to the least controlled one, and every stage must be cleared before the next begins. A proposal can be stopped at any point, and even approval leads into continued monitoring rather than out of the system.

NoteReal Incident / Discovery

In 2009 an insect-resistant genetically modified brinjal, developed for Indian conditions, was recommended for commercial release by the GEAC after its trials. What followed was unusual. The Union Environment Minister, Jairam Ramesh, held a series of open public consultations across several states, in which farmers, scientists, consumer groups and state governments were heard. In February 2010 he announced a moratorium — an indefinite hold on the commercial release — citing the need for greater scientific certainty and wider public confidence. The episode is instructive because the science had cleared the crop while the decision-making process had not: it shows that in a democracy the final release of a GMO is a public decision as much as a technical one.

GEAC in India’s Biosafety Framework

GEAC operates under national laws such as the Environment Protection Act, and follows both national and international biosafety guidelines to ensure the safe use of biotechnology. Its importance lies in four things it delivers:

1. It ensures the safe application of genetic engineering.
2. It protects environmental and human health.
3. It maintains public confidence in biotechnology.
4. It supports sustainable development.

NoteExam Corner

Q. Once GEAC has approved a GM crop, why does it keep monitoring it?

A. Because approval rests on trials of limited size and duration, while commercial cultivation covers vast areas over many seasons. Effects that are too rare or too slow to appear in a trial — insect populations developing resistance, gene flow into wild relatives, changes in soil organisms — can only be detected once the crop is widely grown. Monitoring is how the system catches what testing could not.

NoteCuriosity Corner

Q4. Who in India decides whether a genetically modified crop may be planted in an open field?

A. The Genetic Engineering Approval Committee, working under the Ministry of Environment, Forest and Climate Change. It authorises and monitors confined and open field trials, assesses the environmental and health risks, and grants or refuses approval for environmental release and commercial cultivation — after which it continues to monitor compliance. Its clearance is scientific and regulatory; as the brinjal episode shows, the government may still take the wider public view into account before a crop actually reaches farmers’ fields.

2.9 Biotechnology Organisations: Global and Indian Scenario

Biotechnology does not advance through individual laboratories alone. Progress depends on the combined effort of research institutes, government agencies, international organisations and biotechnology industries, which together carry out basic and applied research, frame policy, provide training and funding, and manufacture products at scale.

For this chapter you need to recognise these bodies by name and know, in a line, what each of them does.

The Global Scenario

Biotechnology today is a worldwide enterprise, with research concentrated in North America, Europe, Japan, China and India, and with a growing share of manufacturing based in India. Two international bodies are worth naming at this stage because you will meet them again.

The National Centre for Biotechnology Information (NCBI) in the United States maintains major biological databases and bioinformatics tools used by researchers everywhere. The European Molecular Biology Laboratory (EMBL), with its headquarters in Germany and outstations in several European countries, carries out molecular and structural biology research and hosts the European Bioinformatics Institute (EBI).

Their databases and search tools are studied in detail in Class XII, under bioinformatics.

The Indian Scenario

India’s strength in biotechnology rests on an unusual combination: a large network of publicly funded institutes and councils on one side, and a vaccine and biopharmaceutical industry of global scale on the other. India is among the world’s largest producers of vaccines, and Indian firms supply recombinant proteins and biosimilars to many countries.

The organisations named in your syllabus are listed below.

Organisation	Full name	Principal concern
NBTB	National Biotechnology Board	The first national body set up to promote and coordinate biotechnology in India
DBT	Department of Biotechnology	Policy, funding and promotion of biotechnology research, education and industry
DST	Department of Science and Technology	Funding and coordination of science and technology research across disciplines
CCMB	Centre for Cellular and Molecular Biology	Research in cell biology, molecular biology, genetics and evolution
ICGEB	International Centre for Genetic Engineering and Biotechnology	Genetic engineering and molecular medicine research, and training of scientists
ICMR	Indian Council for Medical Research	Coordination and funding of biomedical and health research
ICAR	Indian Council for Agricultural Research	Coordination of agricultural research, education and crop improvement

Two relationships in that table are worth noting. The National Biotechnology Board, set up in the early 1980s, was India’s first organised attempt at a national biotechnology programme; it laid the foundation on which the Department of Biotechnology was established in 1986 as a full government department. And ICGEB, though it has a major centre in New Delhi, is an international organisation rather than a purely Indian one — which is why it appears in both the global and the Indian picture.

Diagram

Fig. 2.7 – A chart of India’s biotechnology framework: at the top, Ministry of Science and Technology with DBT and DST beneath it; alongside, ICMR under health and ICAR under agriculture; below, research institutes such as CCMB and the international centre ICGEB; at the base, biotechnology industry

NoteSide Note

Alongside these public bodies, Indian industry contributes substantially to the same field — the Serum Institute of India in vaccine manufacture and Biocon in biopharmaceuticals and enzymes are the best-known examples. For the examination, you are expected to know the names and broad roles of the organisations listed above, not their detailed histories.

NoteExam Corner

Q. Why does a single country need so many separate bodies for one subject?

A. Because they answer to different needs. DBT and DST fund and coordinate research; ICMR and ICAR direct it towards health and agriculture respectively; CCMB and similar institutes actually perform the research; and GEAC, from the previous section, regulates what may be released. Funding, performing and regulating are deliberately kept in different hands, so that no single body both does the work and judges its safety.

2.10 Summary

1. Biotechnology is an interdisciplinary field. It draws on biology for the organism, chemistry for the molecules, physics for instrumentation, mathematics and statistics for design and analysis, engineering for scale-up, and computer science and bioinformatics for handling data. It belongs to no single branch of science and acts as a bridge between them.

2. Its importance lies in five areas: agriculture, where it overcomes species barriers and reduces chemical use; healthcare, where it gives safer, more specific medicines; industry, where enzymes replace harsh chemicals; the environment, where organisms degrade pollutants; and research itself, which it has transformed through genomics, proteomics and bioinformatics.

3. The branches of biotechnology are named after the areas they serve — agricultural (plant), animal, medical, industrial, microbial, immunology and health care, nanobiotechnology, and energy and environmental biotechnology. The same core techniques reappear across several branches.

4. Intellectual Property Rights are legally enforceable rights over intellectual creations, giving the creator exclusive control for a specified period. In exchange for that temporary monopoly, the invention is disclosed publicly.

5. A discovery is the recognition of something that already exists in nature and is not patentable. An invention is a new product or process created by human intervention, and may be patented if it also meets the legal criteria.

6. There are six forms of protection. A patent covers a new, non-obvious and industrially applicable invention for 20 years from filing. A trademark protects a distinctive name or logo. A trade secret protects confidential information for as long as secrecy lasts. Copyright protects the expression of an idea, for the author’s lifetime plus 60 years in India. A Geographical Indication protects the link between a product and its region of origin. Plant Breeders’ Rights under the PPV and FR Act, 2001 protect new plant varieties while preserving farmers’ rights to save and reuse seed.

7. The right form of protection is chosen according to what is being protected and how easily a competitor could work it out: patent where the product reveals the invention, trade secret where it does not, trademark for identity, copyright for written and software work, GI for a regional product, and PPV and FR registration for a new variety.

8. ELSI refers to the ethical, legal and social issues raised by biotechnology. IVF is the standard example, raising questions of autonomy, equality of access, protection of vulnerable groups, respect for human life, commercialisation of reproduction and use of public funds. Legal issues centre on GMO regulation, patenting of living material and genetic privacy; social issues on genetic discrimination, unequal access and public mistrust.

9. Biosafety is the set of measures ensuring the safe handling, containment and use of biological agents and GMOs. Because a released organism can reproduce and spread, control must precede release. Key concerns are environmental release of GMOs, genetic contamination of non-GM crops, laboratory biosafety, and human health risk assessment for toxicity and allergenicity.

10. The Genetic Engineering Approval Committee (GEAC), under the Ministry of Environment, Forest and Climate Change, is India’s apex regulator for genetically engineered organisms. Its objectives are to protect human health and the environment, regulate the use and release of GMOs, ensure compliance with biosafety standards and promote responsible application of biotechnology. It approves GMOs, regulates field trials, assesses environmental and health risk, monitors after approval, frames biosafety guidelines and advises government.

11. India’s biotechnology framework rests on NBTB, DBT, DST, CCMB, ICGEB, ICMR and ICAR, with NCBI and EMBL as major international bodies. Funding, research and regulation are deliberately kept in separate hands.

Flowchart

FC 2.4 – The chapter’s overall sequence: interdisciplinary foundations → importance across sectors → branches of biotechnology → intellectual property and its six forms → ethical, legal and social issues → biosafety of GMOs → regulation by GEAC → the institutions that fund, perform and coordinate the work

2.11 Key Terms

1. Interdisciplinary field a field that draws principles and techniques from several sciences and from engineering, and belongs exclusively to none of them.

2. Bioinformatics the use of computer science to store, analyse and interpret large biological datasets such as genome and protein sequences.

3. Bioreactor a vessel designed to grow organisms or run enzyme reactions under controlled conditions on a large scale.

4. Species barrier the natural obstacle that prevents useful characters from being bred between unrelated species.

5. Agricultural biotechnology the branch that uses biological techniques to improve crop plants and farm animals while keeping farming environmentally sustainable.

6. Genetically modified (GM) crop a crop into which a chosen gene has been deliberately introduced to give it a new, useful character.

7. Micropropagation rapid multiplication of disease-free plants from small pieces of tissue grown in culture.

8. Biofertiliser a preparation of living organisms used in place of chemical fertiliser to improve soil nutrient supply.

9. Biopesticide a pest-control agent of biological origin, used as an eco-friendly alternative to chemical pesticides.

10. Animal biotechnology the branch that uses modern biological techniques to improve animal breeding, health and productivity, and to obtain useful products from animals or animal cells.

11. Embryo transfer technology collection of embryos from a genetically superior female and their transfer into recipient females that carry the pregnancies.

12. Medical biotechnology the branch concerned with developing medicines, diagnostic techniques and treatments for human disease using biological systems.

13. Recombinant protein a protein produced by a host organism carrying an introduced gene from another species.

14. ELISA Enzyme Linked Immuno Sorbent Assay; an immunodiagnostic test used for the early detection of disease.

15. Industrial biotechnology the branch that uses microorganisms and their enzymes for large-scale manufacture of products by environmentally friendly processes.

16. Microbial biotechnology the branch that uses bacteria, fungi, algae and viruses to obtain useful products and services.

17. SCP Single Cell Protein; protein obtained from cultured microbial cells and used as an alternative protein source.

18. Monoclonal antibody a preparation in which every antibody is identical and recognises a single target, giving very high specificity.

19. Hybridoma technology the method by which monoclonal antibodies are produced.

20. Nanobiotechnology the branch that designs and uses materials and devices at the nanometre scale for biological and medical applications.

21. Environmental biotechnology the branch that uses biological processes and organisms to control pollution and to produce renewable energy.

22. Bioremediation the use of living organisms to break down pollutants such as oil, heavy metals and toxic wastes into less harmful substances.

23. Intellectual Property Rights (IPRs) legally enforceable rights over intellectual creations, giving the creator exclusive control over their use and commercial exploitation for a specified period.

24. Discovery the recognition of a substance, organism or natural law that already exists in nature; not patentable.

25. Invention a new and non-obvious product or process created by human effort; patentable if it also meets the legal criteria.

26. Technology transfer the licensed passing of a protected invention from a research laboratory to an industry able to manufacture it.

27. Patent an exclusive right granted by the government over a new, useful and non-obvious invention, valid for 20 years from the date of filing.

28. Novelty the requirement that an invention must not have been disclosed anywhere in the world before filing.

29. Inventive step the requirement that an invention must not be obvious to a person skilled in the relevant scientific field.

30. Industrial applicability the requirement that an invention must have a practical and useful application.

31. Claims the part of a patent document that defines the legal scope and extent of the protection granted.

32. Trademark a distinctive word, name, symbol, logo or design that identifies whose goods or services a product is.

33. Trade secret confidential business information protected only for as long as secrecy is maintained.

34. Copyright the right over original literary, artistic, scientific and educational works, protecting the expression of an idea rather than the idea itself.

35. Geographical Indication (GI) a sign used on a product whose distinctive qualities or reputation arise from the region it comes from.

36. PBR Plant Breeder’s Right; protection given to a new plant variety developed through breeding and selection.

37. Farmers’ Right the right of a farmer to save, use, exchange and sell seed from their own harvest.

38. PPV and FR Act, 2001 the Protection of Plant Varieties and Farmers’ Rights Act, Indian legislation that balances the rights of breeders, farmers and researchers.

39. ELSI Ethical, Legal and Social Issues; the moral, legal and societal concerns raised by the development and application of biotechnology.

40. IVF In-Vitro Fertilization; fertilisation of an egg by sperm outside the body, followed by transfer of the embryo into the uterus.

41. Genetic discrimination unfair treatment of a person, as in employment or insurance, on the basis of their DNA information.

42. Biosafety the measures, practices and regulations ensuring safe handling, containment and use of biological agents and GMOs.

43. GMO a genetically modified organism; an organism whose genetic material has been deliberately altered.

44. Genetic contamination the unintended mixing of genetic material from GM organisms with non-GM crops.

45. Buffer zone a strip of unmodified plants grown around a GM plot to limit the spread of pollen.

46. Allergenicity the capacity of a substance, such as a newly introduced protein in a GM food, to provoke an allergic reaction.

47. PPE personal protective equipment worn in the laboratory to prevent exposure to hazardous biological agents.

48. GEAC Genetic Engineering Approval Committee; India’s apex authority for approving and regulating genetically engineered organisms and products.

49. NBTB National Biotechnology Board; the first national body set up to promote and coordinate biotechnology in India.

50. DBT Department of Biotechnology; the government department responsible for policy, funding and promotion of biotechnology in India.

51. DST Department of Science and Technology; the department that funds and coordinates science and technology research in India.

52. CCMB Centre for Cellular and Molecular Biology; an Indian institute researching cell biology, molecular biology, genetics and evolution.

53. ICGEB International Centre for Genetic Engineering and Biotechnology; an international centre, with a major campus in New Delhi, working on genetic engineering and molecular medicine.

54. ICMR Indian Council for Medical Research; the national body coordinating and funding biomedical and health research.

55. ICAR Indian Council for Agricultural Research; the national body coordinating agricultural research, education and crop improvement.

56. NCBI National Centre for Biotechnology Information; the United States body maintaining major biological databases and bioinformatics tools.

57. EMBL European Molecular Biology Laboratory; the European centre for molecular and structural biology research, which hosts the EBI.

58. EBI European Bioinformatics Institute; the bioinformatics arm hosted by EMBL.

2.12 Points to Ponder

1. Biotechnology is described as a bridge between disciplines rather than a branch of any one of them. If you had to remove one contributing discipline — chemistry, physics, mathematics, engineering or computer science — which loss would cripple the subject most severely, and why?

2. A patent is granted only in exchange for full public disclosure of the invention. Consider whether society gets the better side of this bargain, or the inventor does, and whether your answer changes if the invention is a life-saving medicine rather than an industrial enzyme.

3. A trade secret can last forever while a patent expires in twenty years. If unlimited protection is available without any filing cost, why does anyone choose to patent at all?

4. The law says a naturally occurring gene is a discovery and a modified construct built from it is an invention. Is that line drawn in the right place, given that finding the gene may have taken far more effort and expense than modifying it?

5. Traditional knowledge is usually undocumented, and patent offices work from documents. Suggest ways in which a community’s long-standing knowledge could be recorded so that it is protected, and consider what a community might lose by writing that knowledge down.

6. IVF raises the concern that only wealthier families can afford it. Should a technology be restricted until it can be offered equitably, or made available to whoever can pay while access is gradually widened? Argue both positions before choosing one.

7. GEAC’s scientific clearance of a GM crop has, on occasion, been followed by a government decision not to release it. Does this show that the regulatory system failed, or that it worked? What does your answer imply about who should have the final say over a GMO?

8. A released organism can reproduce; a spilled chemical cannot. Work out what this single difference implies for how biotechnological risk should be assessed, and whether a “safe until proven harmful” approach is defensible for living material.

9. Genetic contamination harms organic farmers who never chose to grow GM crops. Who should bear responsibility for that loss — the GM farmer, the seed company, the regulator, or nobody? Justify your allocation.

10. India funds biotechnology research substantially from public money, yet the resulting products are often sold commercially. Consider what obligations, if any, a company should carry towards the public that helped pay for the underlying research.

11. Public mistrust is listed as a social issue of biotechnology. Reflect on whether mistrust is best answered by better science communication, by stricter regulation, or by giving the public a formal role in approval decisions.

12. Funding bodies, research institutes and the regulator are deliberately kept separate in India’s biotechnology framework. Examine what could go wrong if the same organisation both funded a GM crop’s development and decided whether it was safe to release.

2.13 Objective Questions

1. Which contribution to biotechnology comes primarily from physics?

1. Understanding of metabolic pathways
2. Spectrophotometry, centrifugation and electrophoresis
3. Design of large fermentation vessels
4. Analysis of genome sequences

2. A laboratory result obtained from three replicate tubes must be tested to decide whether the difference between treatments is real. The discipline chiefly involved is:

1. Chemistry
2. Engineering
3. Mathematics and statistics
4. Microbiology

3. Rapid multiplication of disease-free plants from small pieces of tissue is called:

1. Micropropagation
2. Bioremediation
3. Hybridoma technology
4. Embryo transfer

4. Embryo transfer technology in cattle is an application of:

1. Medical biotechnology
2. Animal biotechnology
3. Nanobiotechnology
4. Industrial biotechnology

5. Protease enzymes are added to detergents mainly because they:

1. Whiten fabric by bleaching
2. Remove protein-based stains at lower temperatures
3. Kill bacteria present on clothes
4. Increase the foaming of the detergent

6. The very small size of nanoparticles is useful in medicine because it allows them to:

1. Dissolve faster in water
2. Interact with biological structures of comparable scale
3. Be manufactured more cheaply
4. Survive high temperatures

7. Anaerobic microorganisms converting cattle dung and crop residue into a methane-rich fuel gas is an example of:

1. Genetic contamination
2. Energy and environmental biotechnology
3. Immunology and health care
4. Agricultural biotechnology

8. A scientist isolates a previously unknown bacterium from a hot spring. In law, this is:

1. An invention, and patentable
2. A discovery, and not patentable
3. An invention, but not patentable in India
4. A trade secret

9. Which of the following would most likely fail the criterion of novelty?

1. A process kept confidential until the day of filing
2. A method already published by the inventor in a research journal
3. A modified protein that has industrial use
4. A diagnostic kit developed from known reagents in a non-obvious way

10. The part of a patent document that decides exactly how much of the invention is legally protected is the:

1. Abstract
2. Background of the invention
3. Detailed description
4. Claims

11. A manufacturing process leaves no trace in the finished product and cannot be worked out from it. The most suitable protection is:

1. Patent
2. Trade secret
3. Geographical Indication
4. Copyright

12. Basmati rice and Darjeeling tea are protected as:

1. Trademarks
2. Patents
3. Geographical Indications
4. Trade secrets

13. Under the PPV and FR Act, 2001, a farmer growing a registered variety may:

1. Save and reuse seed from the harvest
2. Sell the saved seed under the breeder’s brand name
3. Register the same variety in their own name
4. Modify the variety and patent it

14. Which concern about IVF is best described as a social rather than an ethical issue?

1. The status of unused embryos
2. High cost limiting access to wealthier families
3. Interference with natural processes
4. Commercialisation of reproduction

15. A buffer zone of unmodified plants is grown around a GM plot mainly to:

1. Improve soil fertility
2. Limit the spread of pollen to neighbouring fields
3. Increase the yield of the GM crop
4. Provide shade to the GM plants

16. Before a GM food is approved, testing for allergenicity is carried out because:

1. GM foods are always toxic
2. A newly introduced protein may provoke an allergic reaction
3. The crop may cross-pollinate with weeds
4. Enzymes are destroyed during cooking

17. GEAC functions under the:

1. Ministry of Environment, Forest and Climate Change
2. Indian Council for Agricultural Research
3. Department of Science and Technology
4. Ministry of Health and Family Welfare

18. Which of these is the first national body set up to promote and coordinate biotechnology in India?

1. DBT
2. NBTB
3. CCMB
4. ICGEB

19. Assertion (A): Biotechnology does not belong to any single branch of science. Reason (R): It draws from biology, chemistry, physics, mathematics, engineering and computer science, and contributes back to all of them.

20. Assertion (A): A patent holder must publish a full description of the invention. Reason (R): Public disclosure is the price paid for a temporary legal monopoly.

21. Assertion (A): A trade secret can, in principle, be protected indefinitely. Reason (R): Protection ends only when the information is disclosed or independently discovered.

22. Assertion (A): An insect-resistant character introduced into a crop could become an ecological problem if it moves into a wild relative. Reason (R): A trait that benefits a crop may give the same competitive advantage to a weed.

23. Assertion (A): Field trials are required even after a GM plant has performed safely in a greenhouse. Reason (R): A greenhouse tests the plant, whereas a field tests its effect on the surrounding ecosystem.

24. Assertion (A): GEAC continues to monitor a GM crop after it has been approved. Reason (R): Effects that are rare or slow to appear cannot be detected within the limited size and duration of trials.

25. Assertion (A): A Geographical Indication belongs to a community of producers rather than to one firm. Reason (R): The qualities it protects arise from the region of origin and not from a single inventor’s work.

26. Assertion (A): Public education and transparent policy are treated as part of biotechnology regulation. Reason (R): A technology the public does not understand tends to be resisted regardless of its merits.

27. A biotechnology company develops insulin using genetically engineered Escherichia coli. This is an example of:

1. Plant biotechnology
2. Traditional breeding
3. Recombinant DNA technology
4. Embryo transfer technology

28. A person receives a therapeutic injection containing human insulin. This insulin is most likely produced by:

1. Extraction from animal pancreas
2. Human stem cells
3. Genetically engineered bacteria
4. Cloning from human liver cells

29. A microbial strain is used to clean oil spills in the ocean. This process is best termed as:

1. Phytoremediation
2. Bioremediation
3. Pasteurisation
4. Biomagnification

30. A farmer in India grows Bt cotton in his fields. He notices a significant decrease in the infestation of bollworms. What could be the reason behind this observation?

1. Use of chemical pesticides
2. Presence of the Bt gene producing insecticidal protein
3. Application of fertilisers
4. Use of hybrid seeds

31. A plant is engineered to tolerate high salt concentrations in soil. This is an application of biotechnology in:

1. Industrial processing
2. Environmental stress tolerance
3. Medicine
4. Animal husbandry

32. A biotechnology firm designs a vaccine that can be eaten in a fruit. What feature makes this an “edible vaccine”?

1. It is plant-based and triggers immunity when consumed
2. It replaces antibiotics
3. It is made from dairy proteins
4. It prevents vitamin deficiency

33. A country bans the use of unregulated GM foods in the market. This decision may be based on concerns related to:

1. Soil fertility
2. Biodiversity
3. Genetic pollution and ethics
4. Crop yield

34. A population of herbicide-resistant weeds emerges in GM crop fields. This could result from:

1. Mutation in GM plants
2. Transfer of the resistance gene from crops to weeds
3. Overuse of pesticides
4. Use of antibiotics

35. For this and the assertion–reason questions that follow, choose one option: (a) both Assertion and Reason are true and the Reason is the correct explanation of the Assertion; (b) both are true but the Reason is not the correct explanation; (c) the Assertion is true but the Reason is false; (d) both the Assertion and the Reason are false.

1. Assertion (A): A patent grants the inventor exclusive rights to make, use and sell the invention. Reason (R): Patents are granted for naturally occurring substances without any modification.
2. Assertion (A): Copyright protects literary, musical and artistic works. Reason (R): Copyright also protects the method of making a pharmaceutical drug.
3. Assertion (A): Trade secrets are not disclosed to the public. Reason (R): Trade secrets are protected only when registered with international agencies.
4. Assertion (A): In India, copyright in a literary work lasts for 60 years after the death of the author. Reason (R): Copyright protects the ideas and concepts of the author.
5. Assertion (A): Discoveries and natural phenomena such as gravity or photosynthesis are not patentable. Reason (R): Discoveries are naturally occurring phenomena and not human-made inventions.
6. Assertion (A): Trademarks help consumers distinguish between products of different brands. Reason (R): Trademarks are symbols, names or logos used for identification of goods or services.
7. Assertion (A): A geographical indication (GI) can help promote traditional and regional products globally. Reason (R): A GI tag is granted to any new invention that solves a technical problem.
8. Assertion (A): A compulsory licence can be issued by the government during a national emergency. Reason (R): Compulsory licences allow others to use a patent without the owner’s permission under certain conditions.
9. Assertion (A): Bt cotton is a genetically modified crop that is resistant to insect pests. Reason (R): It contains a gene from Bacillus thuringiensis that produces a protein toxic to certain insects.
10. Assertion (A): Bioremediation uses microorganisms to clean up environmental pollutants. Reason (R): Certain microbes can metabolise toxic substances into less harmful compounds.
11. Assertion (A): Bioinformatics is essential in analysing genomic data. Reason (R): It combines biology, computer science and statistics to interpret biological information.
12. Assertion (A): Industrial biotechnology can lead to sustainable production processes. Reason (R): It uses biological systems to produce chemicals and materials, reducing reliance on fossil fuels.

36. Fill in the blank: Biotechnology is regarded as an __________ field because it integrates knowledge from several scientific disciplines.

37. Fill in the blank: The gene used in Bt cotton is obtained from the bacterium __________.

38. Fill in the blank: Recombinant human insulin is commonly produced using __________ as a host organism.

39. Fill in the blank: Patents are generally valid for __________ years from the date of filing.

40. Fill in the blank: ELISA is widely used as an __________ diagnostic technique.

41. Fill in the blank: Trade secrets remain protected only as long as __________ is maintained.

42. Fill in the blank: Geographical Indications protect products based on their __________ of origin.

43. Fill in the blank: The regulatory authority responsible for approval of GMOs in India is __________.

44. Fill in the blank: ELSI refers to Ethical, Legal and __________ Issues.

45. Fill in the blank: The Protection of Plant Varieties and Farmers’ Rights Act was enacted in the year __________.

2.14 Check Your Concepts

1. Biology is called the “core” of biotechnology, yet a biologist alone cannot run a biotechnology industry. Explain why, naming at least three other disciplines and the specific gap each one fills.

2. A microbe that grows well in a laboratory flask often fails when the same culture is scaled up to a large tank. Which discipline addresses this problem, and what factors must it control?

3. Traditional breeding cannot transfer a bacterial gene into a plant, but biotechnology can. Explain what makes the difference, and give one advantage and one concern that follows from this ability.

4. Industrial processes using enzymes are described as cleaner and more energy-efficient than chemical processes. Explain the property of enzymes that makes both claims true.

5. The Bt protein kills certain insect larvae but is harmless to humans who eat the crop. Explain the biological basis of this difference.

6. Penicillin was discovered from one species of Penicillium but is manufactured commercially using another. What does this tell you about the difference between a discovery strain and a production strain?

7. Match each application with the correct branch of biotechnology: (i) biosensor for disease detection, (ii) sewage treatment, (iii) monoclonal antibodies for cancer therapy, (iv) micropropagation of banana plants, (v) production of Single Cell Protein.

8. Microbial biotechnology and industrial biotechnology overlap heavily. State what distinguishes them, and give one application that could reasonably be placed in either.

9. A researcher finds a gene in a wild plant that confers drought tolerance, and then builds a construct that transfers it into a crop. Which part of this work is a discovery and which is an invention? Justify your division.

10. Compare a patent and a trade secret under the headings: disclosure, duration, cost, and protection against independent discovery. State which you would choose for a fermentation process whose details cannot be deduced from the product, and why.

11. Why is the requirement of an “inventive step” needed in addition to novelty? Describe what patent law would look like if novelty alone were sufficient.

12. A scientist presents a new diagnostic method at a conference and files a patent application three months later. What difficulty is the application likely to face, and which criterion is at risk?

13. Arrange these in the correct sequence for a GM crop reaching farmers’ fields, and state what each stage is meant to reveal: open field trial with monitoring, laboratory work under containment, post-release monitoring, confined field trial, greenhouse trial, GEAC evaluation.

14. A team wants to protect four things: a new fermentation process, the brand name of the product, the user manual, and a new plant variety they have bred. Assign the correct form of protection to each, with a one-line justification.

15. Explain why a Geographical Indication, and not a patent, is the appropriate protection for a regional agricultural product whose qualities arise from where it is grown.

16. Traditional knowledge practised for centuries should fail the novelty test, yet patents on such uses have sometimes been granted. Explain why this happens and what has been done in India to prevent it.

17. Sort the six ethical concerns associated with IVF under the three ELSI headings — ethical, legal and social — and explain any concern that you feel belongs under more than one heading.

18. “Ethics identifies what ought to happen; law is how a society makes it happen.” Illustrate this statement using any one issue raised by biotechnology.

19. What happens if a GM crop is released without staged field trials? Trace the possible consequences for biodiversity, for neighbouring non-GM farmers, and for public confidence in biotechnology.

20. A spilled chemical stays where it falls; a released organism does not. Explain how this single difference changes the way biotechnological risk must be assessed.

21. An organic farmer’s crop is found to contain genetic material from a neighbour’s GM variety. Name the phenomenon, explain how it most likely occurred, and suggest two preventive measures.

22. A student prepares culture media, autoclaves the glassware, but wipes the bench only with a dry cloth and discards used plates directly into the waste bin. Identify the biosafety errors and state the correct procedure for each.

23. Why does GEAC continue to monitor a GM crop after granting approval, when the crop has already cleared every stage of testing?

24. Label the stages of the GEAC approval process shown in a flow diagram, from the development of a GMO to post-release monitoring, and state at which stage a proposal can first be rejected.

25. India keeps the bodies that fund research, perform research and regulate release in separate hands. Explain the reasoning behind this separation, using GEAC and DBT as your examples.

26. Distinguish between the roles of ICMR and ICAR, and state which of the two would be chiefly concerned with a new drought-tolerant rice variety.

27. Name any two applications of medical biotechnology.

28. Mention one ethical concern related to IVF.

29. State one function of the Genetic Engineering Approval Committee (GEAC).

30. Why is biotechnology described as an interdisciplinary science?

31. What is meant by industrial applicability in patent law?

32. What is Single Cell Protein (SCP)?

33. What is genetic contamination?

34. State one advantage of trade secrets over patents.

35. What is the role of bioinformatics in biotechnology?

36. Explain the importance of biotechnology in agriculture.

37. Why are genetically modified plants and animals not patentable in India?

38. List and explain the essential criteria required for patentability.

39. Describe the role of biotechnology in environmental protection.

40. Explain the concept of I-PROTECT in relation to Intellectual Property Rights.

41. Describe any three applications of industrial biotechnology.

42. Differentiate between a patent and a trademark, with suitable examples.

43. Explain the significance of biosafety in modern biotechnology.

44. Why is regulation of GMOs necessary in India?

45. Discuss biotechnology as a truly interdisciplinary field, highlighting the contribution of different branches of science.

46. Describe the major branches of biotechnology with suitable examples.

47. Discuss the Ethical, Legal and Social Issues (ELSI) associated with biotechnological advancement.

48. Explain the role and importance of Intellectual Property Rights in the development of biotechnology.

49. Critically evaluate the advantages and disadvantages of the patent system in biotechnology.

50. Explain the objectives and functions of the Genetic Engineering Approval Committee (GEAC).

51. Describe the different types of Intellectual Property Rights relevant to biotechnology.

52. “Biosafety is essential for sustainable biotechnological development.” Justify this statement.

53. A biotechnology company develops a novel recombinant vaccine. Which type of Intellectual Property Right should be used to protect this invention? Justify your answer.

54. Enzyme-based detergents are considered environmentally friendly. Identify the branch of biotechnology involved and explain why these detergents are energy efficient.

55. Explain why biofertilisers are preferred over chemical fertilisers in sustainable agriculture.

56. During a debate competition, students such as Samreen, Abdul and Rohan discuss the importance of Intellectual Property Rights (IPRs). It is argued that scientific innovations require legal protection to ensure recognition and economic benefit to inventors. Explain the need and importance of IPRs in biotechnology.

57. In a diagnostic laboratory, technicians such as Ajitha Nair, Syed Sadiq and Peter D’Silva use ELISA and PCR for early disease detection. These modern methods give faster and more accurate results than traditional diagnostic approaches. Explain how biotechnology has improved disease diagnosis and healthcare.

58. A pharmaceutical company owned by a multinational group sells a patented life-saving drug at a high price. Patients such as Rahul, Amina and Joshua Varghese find it difficult to afford the treatment. Analyse the advantages and limitations of patent protection in such a situation.

2.15 Case-Based Questions

1. A small company wants to manufacture an organic acid used in the food industry. Its biologists select a fungal strain that produces the acid; its chemists work out the pathway and the purification steps; its engineers design a 5,000-litre fermenter with stirring, aeration and cooling; and its analysts run the trial batches through a colorimeter and compare the yields statistically before choosing the final conditions. The first pilot batch, run without cooling, dies within a day.

1. Identify the contribution of each discipline named in the passage.
2. Explain why the batch without cooling failed, and which discipline is responsible for preventing this.
3. State why the company needed statistical analysis rather than simply choosing the batch with the highest yield.
4. Justify the statement that this company’s work could not have been done from within any single science.

2. A research team develops two things during one project: a modified microbial strain that produces an industrial enzyme, and a purification process whose details cannot be deduced from the finished enzyme. The team also designs a distinctive logo for the product and writes a detailed user manual for customers. Before filing anything, one member proposes publishing the whole work in a journal to establish priority.

1. Recommend the appropriate form of protection for each of the four items, with reasons.
2. Explain the risk in the proposal to publish before filing.
3. State one advantage and one disadvantage the team accepts by choosing a patent for the strain.
4. Suggest why the team might license the patent widely rather than keep exclusive use of it.

3. A regional variety of chilli, grown for generations in a particular district, is known for a flavour that growers attribute to the local soil and climate. A company in another country files a patent claiming the use of an extract of this chilli as a food preservative — a use the district’s farmers have relied on for as long as anyone remembers. The farmers have no written record of their practice.

1. On which criterion of patentability is the claim most vulnerable, and why?
2. Explain why the absence of written records makes the farmers’ position difficult.
3. Name the form of protection best suited to the chilli’s link with its district, and state whom that protection belongs to.
4. Suggest two measures a country can take to protect such community knowledge in advance.

4. A couple is advised to undergo IVF at a private clinic. The treatment costs more than their annual income, and they raise a loan for it. Several embryos are produced, of which two are transferred and the rest frozen. The clinic offers, for an additional fee, to screen the embryos and share information about the traits each carries.

1. Identify one ethical, one legal and one social issue raised by this situation.
2. Explain the concern that arises from the offer to screen embryos for traits.
3. State the question that the surplus frozen embryos raise, and why opinions differ on it.
4. Suggest where a regulator might reasonably draw the line between permitted and prohibited screening.

5. A GM variety of a food crop has cleared laboratory and greenhouse testing and is now in confined field trials. Farmers nearby grow the same crop conventionally, and one of them supplies an export market that does not accept GM produce. During a public hearing, some participants demand immediate approval to raise yields, while others demand that the trials be stopped altogether.

1. Identify two ecological risks that the confined field trial is designed to reveal.
2. Explain the specific commercial risk faced by the exporting farmer, and name the phenomenon involved.
3. Describe the role of GEAC at this stage and after any approval is granted.
4. Explain why a regulator might reject both demands made at the hearing.

6. A publicly funded laboratory develops a diagnostic kit for a disease common in rural districts. The technology is patented and licensed exclusively to one manufacturer, which sets a price well above what the district hospitals can pay. A public interest group argues that taxpayers funded the work and should not be priced out of its benefit; the manufacturer argues that without exclusivity it would not have invested in production.

1. State the advantage and the limitation of patent protection illustrated by this case.
2. Explain the argument on each side without taking a position.
3. Suggest two mechanisms that could widen access without removing the incentive to innovate.
4. Explain how the outcome might differ if the laboratory had licensed the patent non-exclusively.

7. A genetically modified crop is released into the environment without proper biosafety assessment.

1. Identify the biosafety concern involved.
2. Name the regulatory authority responsible for preventing such incidents.
3. Mention two possible environmental consequences.

8. A farmer saves seeds from a newly developed plant variety registered under the PPV and FR Act and uses them for the next sowing season.

1. Is the farmer legally permitted to do so?
2. Which provision of the PPV and FR Act supports this right?
3. How does this Act balance the interests of farmers and plant breeders?

9. During a biotechnology seminar attended by students such as Ajay, Ayesha Verma and Gurbachan, experts explain that biotechnology is an interdisciplinary science. They describe how knowledge from biology, chemistry, physics, engineering and computer science is integrated to develop useful products.

1. Why is biotechnology called an interdisciplinary field?
2. Explain the role of any two disciplines involved in biotechnology.
3. How does engineering contribute to biotechnology?
4. Give one real-life example where multiple disciplines are applied together.

10. A biotechnology company led by scientists such as Dr Lynchu Iyer, Dr Naqvi and Dr Gerrod develops a new recombinant vaccine after years of research. The team wants to protect the invention legally and ensure commercial benefit, while also following ethical and regulatory guidelines before releasing it.

1. Which type of IPR should the company apply for?
2. Mention two criteria required for obtaining this protection.
3. Why is legal protection important for such innovations?
4. What ethical concern may arise in this situation?

11. A genetically modified (GM) crop is introduced in a farming region where farmers such as Suresh, Ivan and Martina cultivate nearby fields. The crop is released without proper biosafety assessment and over time it begins to affect surrounding plant species. Scientists raise concerns about ecological imbalance and environmental safety.

1. Identify the biosafety issue involved.
2. Name the regulatory authority responsible in India.
3. Mention two possible environmental risks.
4. Why is biosafety assessment essential before release?

12. Malti is part of a biotechnology advisory team that includes experts such as Dr Kavita Menon, Dr Arif Siddiqui and Dr David Thomas. Her team is asked to design a plan for the safe release of a genetically modified crop in India. The plan must ensure biosafety, regulatory compliance and address the ethical concerns of diverse communities.

1. Outline the steps involved before releasing the GM crop.
2. Mention the role of GEAC in this process.
3. Suggest two biosafety measures to be followed.
4. How will Malti address public concerns and ethical issues?